menu
    • menu
    [{"orgOrder":0,"company":"Jiangsu Wuzhong Pharmaceutical Group","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Endostatin","moa":"Prolactin receptor (PRLR)","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Wuzhong Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Wuzhong Pharmaceutical Group \/ Denovo Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Wuzhong Pharmaceutical Group \/ Denovo Biopharma"},{"orgOrder":0,"company":"Jiangsu Wuzhong Pharmaceutical Group","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Endostatin","moa":"Prolactin receptor (PRLR)","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Wuzhong Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Wuzhong Pharmaceutical Group \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Wuzhong Pharmaceutical Group \/ Tigermed"}]

    Find Clinical Drug Pipeline Developments & Deals by Jiangsu Wuzhong Pharmaceutical Group

    Menu

    Jiangsu Wuzhong Pharmaceutical Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jiangsu Wuzhong Pharmaceutical Group

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Jiangsu Wuzhong Pharmaceutical Group

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Endostatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Denovo Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Denovo Biopharma Acquires a Novel Late-Stage Oncology Drug and Expands into Protein Therapeutics

                            Details : DB108 is a recombinant protein drug that inhibits tumor growth and metastasis by inhibiting angiogenesis. Denovo gains global rights (except China) to develop, manufacture and commercialize endostatin from Jiangsu Wuzhong Pharmaceutical Group Corporation...

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            December 10, 2020

                            Lead Product(s) : Endostatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Denovo Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jiangsu Wuzhong Pharmaceutical Group

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Jiangsu Wuzhong Pharmaceutical Group

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Endostatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Tigermed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung C...

                            Details : Sulijia (Endostatin) is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Sulijia

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 17, 2017

                            Lead Product(s) : Endostatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Tigermed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth